Once monthly CRF2 peptide agonist (COR-1389)
A very long acting CRF2 peptide agonist, COR-1389, has been developed allowing once monthly subcutaneously administration for the treatment of chronic diseases of high unmet medical needs, such as right heart failure, obesity and sarcopenia. Preclinical proof of concept has been established with CRF2 agonists for these indications. In preclinical models of right heart failure, COR-1389 has been shown to improve cardiopulmonary function and right ventricular hypertrophy. In obesity models, COR-1389 lessened body weight by reducing fat mass while preserving muscle mass, and is expected to ameliorate obesity-related comorbidities. Finally CRF2 agonists have been reported to reduce skeletal muscle mass wasting, improve muscle strength and exercise capacity in multiple preclinical models of sarcopenia.
COR-1389 is currently in phase 1.